Rationale, design and methods of the ESPRIT study: Energy, Sexual desire and body PropoRtions wIth AndroGel, Testosterone 1% gel therapy, in hypogonadal men.
Hypogonadism is associated with a range of disease states that have significant effects on morbidity and mortality, and also affect quality of life. The ESPRIT study (Energy, Sexual desire and body PropoRtions wIth AndroGel, Testosterone 1% gel therapy) is a 6-month, multinational, open label, observational study in hypogonadal men being treated with transdermal AndroGel in usual daily clinical practice; 1,700-2,400 patients will be enrolled in Canada, Germany, Central and Eastern Europe, Russia and the Middle East. The main objective will be to evaluate the effect of AndroGel on symptoms of hypogonadism and quality of life as assessed by the Aging Males' Symptoms scale. Further objectives include evaluating the effect and time to onset of improvement in erectile dysfunction and libido/sexual desire (International Index of Erectile Function), fatigue (Multi-dimensional Fatigue Index) and body composition (waist circumference, body mass index). Subgroup analyses will be performed: <50 years versus > or = 50 years; absence versus presence of metabolic syndrome. The safety of AndroGel will also be assessed. The study population will consist of newly diagnosed hypogonadal men (age > or = 18 years), in whom testosterone deficiency has been confirmed by clinical features and biochemical tests according to international guidelines, who are currently being prescribed AndroGel (testosterone 1% gel, starting dose 50 mg testosterone per day).
Behre
Hermann M
HM
Centre of Reproductive Medicine and Andrology, University Hospital Halle, Germany.
Heinemann
Lothar
L
Morales
Alvaro
A
Pexman-Fieth
Claire
C
D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D000368:Aged; D000728:Androgens / Q000008:administration & dosage / Q000627:therapeutic use*; D001823:Body Composition / Q000187:drug effects; D007172:Erectile Dysfunction / Q000188:drug therapy; D005782:Gels; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy*; D007989:Libido / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D019370:Observation; D011788:Quality of Life; D013739:Testosterone / Q000008:administration & dosage / Q000627:therapeutic use*
D000728:Androgens; D005782:Gels; D013739:Testosterone